Curadel Pharma published a STAT article highlighting the need for innovative approaches to realize the full potential of radiopharmaceuticals and the strategy behind its novel zwitterionic pipeline.

Curadel Pharma is an audacious innovator aiming to prevent tumor resistance via disruptive zwitterionic radiopharma technology. Its novel, pan-tumor platform prevents tumor regrowth and resistance while eliminating collateral damage to healthy tissues. Curadel’s lead candidate, CPI-003, represents a potential best-in-class zwitterionic targeted alpha therapy (TAT) initially focused on the treatment of challenging rare cancers. The company is also developing image-guided surgical drugs. Its late-stage drug for ureter imaging is currently under evaluation in a pivotal trial. Curadel was founded by zwitterionicity pioneer John V. Frangioni, M.D., Ph.D., Professor of Medicine (Emeritus) and Professor of Radiology (Emeritus) at Harvard Medical School.